CD19 and neoplasm: One arm of a BiTE/bsAb binds to a surface antigen of a tumor cell (e.g., CD19 or BCMA), whereas the other arm binds to the CD3 receptor of a T-cell initiating a T-cell receptor-independent killing of cancer cells.